Download presentation
Presentation is loading. Please wait.
Published byLucas Max Ström Modified over 5 years ago
1
Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. Schematic representation of available clinical data including preliminary antitumor activity and main toxicities observed with BET inhibitors. AL, acute leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; NUT ca, NUT carcinoma; GLB, glioblastoma; GI, gastrointestinal; n, number of patients included; CR, complete remission; PR, partial remission; NR, no response. *This study included 70 patients at the time of reporting, and preliminary activity was reported in 10 patients with NUT carcinoma (67). Cited references: Berthon, et al. (60); Amorim, et al. (61); Stathis, et al. (64); Massard, et al. (65); Hottinger, et al. (69); Abramson, et al. (62); O'Dwyer, et al. (67); Shapiro, et al. (66); Postel-Vinay, et al. (70). Anastasios Stathis, and Francesco Bertoni Cancer Discov 2018;8:24-36 ©2018 by American Association for Cancer Research
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.